Switching from Intravenous to Subcutaneous Infliximab in Psoriasis: A Case Series on Efficacy and Treatment Satisfaction.

This pattern reflects an interesting trend: SC-IFX did not worsen treatment clinical status and was rather associated with improvement in 18.2% of subjects ( Figure 2 and Figure 3 ). 3.4.

also in 1,024 other papers

TSQM Analyses The TSQM-9 revealed a highly significant difference between IV-IFX and SC-IFX ( Figure 2 ).

also in 83,176 other papers

Finally, PGA analyses showed a trend favoring SC-IFX, suggesting that route switching did not hinder the physician-assessed outcomes ( Figure 2 ).

also in 33,237 other papers